Moleculin Biotech Inc stock is traded at $8.73, with a volume of 25,170. It is up +3.19% in the last 24 hours and down -2.02% over the past month. Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Previous Close:
$8.46
Open:
$8.46
24h Volume:
25,170
Relative Volume:
0.53
Market Cap:
$8.90M
Revenue:
-
Net Income/Loss:
-$30.33M
P/E Ratio:
-
EPS:
-$28.04
Net Cash Flow:
-$24.28M
1W Performance:
+10.51%
1M Performance:
-2.02%
6M Performance:
-82.40%
1Y Performance:
-96.18%
1-Day Range:
$0.00$0.00
1-Week Range:
$7.65$8.96
52-Week Range:
$3.23$253.05
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech IncSector
HealthcareIndustry
BiotechnologyPhone
713-300-5160Address
5300 MEMORIAL DRIVE, HOUSTON, TX, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS